When examining levels of MMR proteins individually, we found that MSH-2 low independently predicted poor outcome in cervical cancer and that MSH-2 low associated with higher mutational burden, RAD50 frameshift mutations, and an immune reactive transcriptome. This evidence concerns the gene MSH2 and cervical carcinoma.